Balchem Corporation · NASDAQ:BCPC
Balchem — Q4 2025 Earnings Presentation
35 slides from Balchem's earnings presentation, Feb 20, 2026
Slide 1: Investor Presentation Q4 2025
Investor Presentation Q4 2025. 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement • During the course of this presentation, management may make forward-looking statements regarding financial performance and future events. • These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "foreca
Slide 3: Agenda
Agenda 01 Q4 2025 Key Takeaways 05 Sustainability 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 3
Slide 4: Q4 Key Takeaways
Q4 Key Takeaways Balchem continues to deliver strong growth +9.8% 1. Great financial performance with strong sales, earnings, and cash flow growth Q4 Sales vs. PY 2. All three business segments delivered solid growth on the top and bottom lines +8.1% 3. Strategic growth initiatives are progressing w
Slide 5: Agenda
Agenda 01 Q4 2025 Key Takeaways 05 Sustainability 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 5
Slide 6: Balchem Corporation At a Glance
Balchem Corporation At a Glance BCPC NASDAQ 2025 Sales $1.0 Billion Approximate number of employees 1,400 2025 Adjusted EBITDA $275 Million Founded in 2025 Adjusted EBITDA margin 1967 26.5% 6
Slide 7: Three Business Segments – 2025 Revenue
Three Business Segments – 2025 Revenue Human Nutrition & Health Animal Nutrition & Health Specialty Products Human Nutrition & Health Animal Nutrition & Health Specialty Products 64% 22% 14% Provides a range of branded specialty Supplies science-based animal feed Provides critical sterilization tech
Slide 8: Balchem Corporation
Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that help make the world a healthier place. Corporate Headquarters: Montvale, NJ 22 Manufacturing Sites 8 Technology Centers 8 Regional Offices 8
Slide 9: Executive Leadership
Executive Leadership Ted Harris Chairman, President, and CEO • Joined Balchem in May 2015 • Prior to Balchem was a Senior VP of Ashland Inc. where he held a series of senior leadership roles over 10+ years • Independent director on the Board of Directors of Pentair plc • MBA from Harvard University
Slide 10: Value Proposition
Value Proposition Technologies Value to our customers • High efficacy nutrients essential for life • Enhanced animal health and feed productivity • Functional ingredient systems formulations and applications expertise • Crop protection and yield improvement • Complete supply chain capabilities and a
Slide 11: Segment Overview
Segment Overview Leveraging Solutions Across Segments Segment Markets Served Solutions 14% Human Nutrition • Nutritional Supplements • Microencapsulation 2025 & Health • Sport & Active Nutrition • Choline and Vitamin K2 22% Revenue • Infant and Toddler Formula • Chelated Minerals by • Healthy Snacki
Slide 12: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Sustainability 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 12
Slide 13: Our Vision is clear – to make the world a healthier place
Our Vision Our Mission is clear – to make is focused – to build a global the world a healthier nutrition and health company place. delivering trusted, innovative and science-based solutions to our customers. Our Core Values Always Collaborating Playing Staying Doing the and Growing to and Acting on
Slide 14: How Do We Make the World a Healthier Place?
How Do We Make the World a Healthier Place? Provide food, beverage, and Improve nutrient bioavailability Support prenatal, infant, and Help farmers grow crops that Provide nutritious foods for dietary supplement ingredients for animals, reducing feed inputs toddler health with targeted are hardier w
Slide 15: Strategic Focus
Strategic Focus 01 02 03 04 Strengthening Driving Organic Strategic M&A Excellence in Positions in Attractive, Growth Execution Growing Markets Building scale, adding Creating new demand Augmenting organic Maintaining a strong adjacent capabilities, through innovation, market growth and accelerating
Slide 16: Growth Platforms
Growth Platforms Multiple Platforms to Drive Growth Above Market Growth Nutrient Delivery Geographic Systems For The Specialty Products Specialty Expansion Dairy Market Nutrients Metalosate® plant micro- nutrient market penetration Expansion into under- Science-backed Rumen-bypass precision served g
Slide 17: Agenda
Agenda 01 Q4 2025 Key Takeaways 05 Sustainability 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 17
Slide 18: Q4 2025 Financial Summary
Q4 2025 Financial Summary Strong sales and profit growth in the fourth quarter Sales Adj. EBITDA Adj. Net Earnings Adj. EPS $M $M $M $/share 9.8% 8.1% 14.8% 15.9% 263.6 67.9 42.3 1.31 240.0 62.8 36.9 1.13 4Q24 4Q25 4Q24 4Q25 4Q24 4Q25 4Q24 4Q25 Strong growth in all three Driven by sales grow
Slide 19: FY 2025 Financial Summary
FY 2025 Financial Summary Sales growth, profit growth, and margin expansion Sales Adj. EBITDA Adj. Net Earnings Adj. EPS $M $M $M $/share 8.8% 9.8% 17.4% 17.8% 1037.2 167.9 5.15 274.9 953.7 250.3 143.0 4.37 FY24 FY25 FY24 FY25 FY24 FY25 FY24 FY25 Strong growth in all three Driven by sales gr
Slide 20: Historical Financials
Historical Financials Consistent performance over the years Sales +8.1% Adj. EBITDA $M CAGR 1,037 $M +9.6% CAGR 275 942 954 250 922 231 216 799 190 174 704 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 Adj. Net Earnings Adj. EPS $M $/share +9.3% 168 CAGR +9.2% 5.15 143 CAGR 131 130 4.3
Slide 21: Capital Allocation Strategy
Capital Allocation Strategy Capital Allocation Priorities Annual Cash Flow and Net Debt Leverage Ratio • Support organic growth opportunities 2.3 • Augment growth with targeted M&A • Diligent debt service 1.6 1.7 1.5 217 • Continue to pay and grow dividend 1.2 1.1 184 • Stock buy-backs for anti-dilu
Slide 22: Free Cash Flow Conversion
Free Cash Flow Conversion Translating profits into cash Free Cash Flow as % of Non-GAAP Net Earnings 116% 109% 107% 105% 103% 103% 102% 102% 93% 100% 79% 69% 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 22
Slide 23: Key Acquisitions
Key Acquisitions Augmenting Organic Growth with Targeted Acquisitions Close to Core Kappa Bioscience • Portfolio extension in high growth specialty vitamin market • Vitamin K2 and MK-7 Albion Minerals Bioscreen • Adjacent product offering • Geographic expansion and Bergstrom Nutrition in high growth
Slide 24: Dividends
Dividends Consistent dividend policy Annual double-digit +10.9% CAGR 0.96 dividend growth for the last decade 0.87 0.79 0.71 0.64 0.58 ($/share) 0.47 0.52 Consistency in 0.34 0.38 0.42 execution 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 24
Slide 25: Agenda
Agenda 01 Q4 2025 Key Takeaways 05 Sustainability 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 25
Slide 26: Recent Sustainability Progress
Recent Sustainability Progress Making the world a healthier place Scope 3 Learn more 7th about our sustainability GHG emissions successfully programs: measured and reported sustainability report released in April 2025 5th anniversary of UN Global Compact Surpassed our 2030 GHG emissions reduction go
Slide 27: Agenda
Agenda 01 Q4 2025 Key Takeaways 05 Sustainability 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 27
Slide 28: Balchem Summary
Balchem Summary A global nutrition and health company delivering trusted, innovative and science-based solutions to our customers Leading positions Creating new Strong financial Proven track in attractive demand through performance, record and markets innovation delivering healthy well positioned ma
Slide 29: Agenda
Agenda 01 Q4 2025 Key Takeaways 05 Sustainability 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 29
Slide 30: Non-GAAP Financial Information
Non-GAAP Financial Information In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this presentation contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial per
Slide 31: Non-GAAP Financial Information
Non-GAAP Financial Information Reconciliation of Non-GAAP Measures to GAAP (Dollars in thousands, except per share data; unaudited) Three Months Year Ended Ended December 31, December 31, Reconciliation of adjusted earnings from operations 2025 2024 2025 2024 GAAP earnings from operations $52,290 $4
Slide 32: Non-GAAP Financial Information
Non-GAAP Financial Information Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA (Dollars in thousands; unaudited) Three Months Year Ended Ended December 31, Ended December 31, 2025 2024 2025 2024 Net earnings – as reported $39,225 $33,583 $154,845 $128,475 Add back: Provision for
Slide 33: Non-GAAP Financial Information
Non-GAAP Financial Information Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate (Dollars in thousands; unaudited) Three Months Year Ended Ended December 31, Ended December 31, 2025 2024 2025 2024 GAAP Income Tax Expense $10,810 $10,901 $44,185 $37,978 GAAP Effec
Slide 34: Non-GAAP Financial Information
Non-GAAP Financial Information (1) Amortization of intangible assets and finance leases: Amortization of intangible assets and finance leases consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets
Slide 35: bailchem
bailchem lve Today. Shape Tomorrow.